Results 21 to 30 of about 10,064 (258)
Frontiers in Endocrinology, 2022 Reducing injection-site pain (ISP) in patients with chronic conditions such as growth hormone deficiency is a valuable strategy to improve patient compliance and therapeutic efficiency.
Bita Taghizadeh +4 more
doaj +1 more source
Pharmaceutics, 2022 The aim of this study was to understand drug solubilization as a function of age and identify drugs at risk of altered drug solubility in newborns and young infants in comparison to adults.
Mariana Guimarães +4 more
doaj +1 more source
Application of In Vivo Imaging Techniques and Diagnostic Tools in Oral Drug Delivery Research
Pharmaceutics, 2022 Drug absorption following oral administration is determined by complex and dynamic interactions between gastrointestinal (GI) physiology, the drug, and its formulation.
Stefan Senekowitsch +15 more
doaj +1 more source
Pharmaceutics, 2023 Medical practitioners commonly use oral and parenteral dosage forms to administer drugs to patients. However, these forms have certain drawbacks, particularly concerning patients’ comfort and compliance.
Avelia Devina Calista Nainggolan +5 more
doaj +1 more source
Bioethical issues in the development of biopharmaceuticals [PDF]
Filozofija i Društvo, 2012 Development of biopharmaceuticals is a challenging issue in bioethics. Unlike conventional, small molecular weight drugs, biopharmaceuticals are proteins derived from DNA technology and hybrid techniques with complex three dimensional structures ...
Todorović Zoran, Protić Dragana
doaj +1 more source
Pharmaceutics, 2020 Biopharmaceutical classification system (BCS) class IV drugs (low-solubility low-permeability) are generally poor drug candidates, yet, ~5% of oral drugs on the market belong to this class.
Milica Markovic +4 more
doaj +1 more source
Subcutaneous Biopharmaceutics: Building tools for a flexible future
British Journal of Pharmacy, 2023 The major biopharmaceutics challenge faced during the development of subcutaneous (SC) drug products is the limited understanding of the physiological factors and the combination product attributes that can impact absorption rate/extent and drug product ...
Kate Louise Harris +4 more
doaj +1 more source
Physiologically Based Biopharmaceutics Model of Apixaban for Biopharmaceutics Risk Assessment. [PDF]
PharmaceuticsBackground/Objectives: This study applies a Physiologically Based Biopharmaceutics Modeling (PBBM) framework to predict the bioavailability (BA) and bioequivalence (BE) of apixaban, a borderline BCS Class III/IV drug.
Paixão P, Petric Z, Morais JAG.
europepmc +2 more sources
Prodrugs for Improved Drug Delivery: Lessons Learned from Recently Developed and Marketed Products
Pharmaceutics, 2020 Prodrugs are bioreversible, inactive drug derivatives, which have the ability to convert into a parent drug in the body. In the past, prodrugs were used as a last option; however, nowadays, prodrugs are considered already in the early stages of drug ...
Milica Markovic +2 more
doaj +1 more source
Metal-organic frameworks for advanced drug delivery
Acta Pharmaceutica Sinica B, 2021 Metal-organic frameworks (MOFs), comprised of organic ligands and metal ions/metal clusters via coordinative bonds are highly porous, crystalline materials.
Siyu He +11 more
doaj +1 more source